Recent U.S. government actions including an Executive Order (EO) on treating serious mental illness herald greater opportunities for psychedelic drug candidates to move from clinical testing to market. Below we summarize what this means for the industry, including legal issues surrounding the “Right to Try” regulatory pathway promoted by the EO. In an Executive Order […]